An overview of class III electrophysiological agents: a new generation of antiarrhythmic therapy.
暂无分享,去创建一个
[1] W. Gould,et al. Sulfonanilides. I. Monoalkyl- and arylsulfonamidophenethanolamines. , 1966, Journal of medicinal chemistry.
[2] T. Narahashi,et al. 3,4-diaminopyridine. A potent new potassium channel blocker. , 1978, Biophysical journal.
[3] J. K. Smallwood,et al. Clofilium and Other Class III Agents , 1989 .
[4] J. Papp,et al. The effect of altered thyroid state on atrial intracellular potentials , 1970, The Journal of physiology.
[5] L. Opie,et al. Serotonin and the heart: effects of ketanserin on myocardial function, heart rate, and arrhythmias. , 1985, Journal of cardiovascular pharmacology.
[6] M. Davies,et al. Attenuation of Class 3 and Sinus Node Effects of Amiodarone by Experimental Hypothyroidism , 1989, Journal of cardiovascular pharmacology.
[7] H. Brasch. Influence of the optical isomers (+)‐ and (−)−naloxone on beating frequency, contractile force and action potentials of guinea‐pig isolated cardiac preparations , 1986, British journal of pharmacology.
[8] T. N. James,et al. Acute effects of amiodarone upon the canine sinus node and atrioventricular junctional region. , 1983, The Journal of clinical investigation.
[9] H. Refsum,et al. Prolonged action potential duration of guinea-pig heart muscle after pethidine. , 1990, Pharmacology & toxicology.
[10] I. Kodama,et al. Effects of OPC‐88117, a new antiarrhythmic agent, on the electrophysiological properties of rabbit isolated hearts , 1989, British journal of pharmacology.
[11] A. Raine,et al. Adaptation to prolonged beta-blockade of rabbit atrial, purkinje, and ventricular potentials, and of papillary muscle contraction. Time-course of development of and recovery from adaptation. , 1981, Circulation research.
[12] A. Brown,et al. 5-Hydroxytryptamine antagonist ICS 205-930 blocks cardiac potassium, sodium and calcium currents. , 1988, The Journal of pharmacology and experimental therapeutics.
[13] J. Hershman,et al. Effects of Desethylamiodarone on Thyroid Hormone Metabolism in Rats: Comparison with the Effects of Amiodarone , 1986, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[14] B. Lucchesi,et al. Antiarrhythmic and antifibrillatory actions of the levo- and dextrorotatory isomers of sotalol. , 1984, Journal of cardiovascular pharmacology.
[15] M. B. Rosenbaum,et al. Control of tachyarrhythmias associated with Wolff-Parkinson-White syndrome by amiodarone hydrochloride. , 1974, The American journal of cardiology.
[16] A. Damato,et al. Electrophysiologic effects of bretylium tosylate on single fibers of the canine specialized conducting system and ventricle. , 1970, The Journal of pharmacology and experimental therapeutics.
[17] Y. Q. Xu,et al. Study of the effects and mechanisms of berberine on slow-response action potentials. , 1990, Journal of electrocardiology.
[18] J. Bigger,et al. Efficacy, safety, and tolerance of d-sotalol in patients with refractory supraventricular tachyarrhythmias. , 1989, American heart journal.
[19] G. Duker,et al. — A new, potent class III antiarrhythmic agent , 1990 .
[20] J. L. Kenyon,et al. 4-Aminopyridine and the early outward current of sheep cardiac Purkinje fibers , 1979, The Journal of general physiology.
[21] D. Wyse,et al. Melperone: Electrophysiologic and Antiarrhythmic Activity in Humans , 1990, Journal of cardiovascular pharmacology.
[22] H. Duff,et al. Amiloride. Antiarrhythmic and electrophysiological activity in the dog. , 1988, Circulation.
[23] A. Kling,et al. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. , 1986, The New England journal of medicine.
[24] D. Wyse,et al. Electropharmacology of amiodarone therapy initiation. Time courses of onset of electrophysiologic and antiarrhythmic effects. , 1989, Circulation.
[25] M. Morad,et al. Tedisamil blocks the transient and delayed rectifier K+ currents in mammalian cardiac and glial cells. , 1990, The Journal of pharmacology and experimental therapeutics.
[26] B Lown,et al. The Coronary Care Unit: New Perspectives and Directions , 1967 .
[27] G. Feld,et al. Effects of N-acetylprocainamide and recainam in the pharmacologic conversion and suppression of experimental canine atrial flutter: significance of changes in refractoriness and conduction. , 1988, Journal of cardiovascular pharmacology.
[28] E. Williams,et al. Effects on cardiac muscle of the β‐adrenoceptor blocking drugs INPEA and LB46 in relation to their local anaesthetic action on nerve , 1971, British journal of pharmacology.
[30] M. Kienzle,et al. Enhanced efficacy of oral sotalol for sustained ventricular tachycardia refractory to type I antiarrhythmic drugs. , 1988, The American journal of cardiology.
[31] M. Bacaner. Quantitative comparison of bretylium with other antifibrillatory drugs , 1968 .
[32] R. DeVita,et al. Rational design of 4-[(methylsulfonyl)amino]benzamides as class III antiarrhythmic agents. , 1987, Journal of medicinal chemistry.
[33] L. Cobb,et al. Prolongation of cardiac refractory times in man by clofilium phosphate, a new antiarrhythmic agent. , 1983, American heart journal.
[34] D. Davey,et al. Synthesis of novel (aryloxy)propanolamines and related compounds possessing both class II and class III antiarrhythmic activity. , 1990, Journal of medicinal chemistry.
[35] E. Platia,et al. Dose‐ranging studies of clofilium, an antiarrhythmic quaternary ammonium , 1984, Clinical pharmacology and therapeutics.
[36] R. Deana,et al. Properties of a new calcium ion antagonist on cellular uptake and mitochondrial efflux of calcium ions. , 1984, The Biochemical journal.
[37] J. Hill,et al. Electrophysiologic effects of amiloride in canine Purkinje fibers: evidence for a delayed effect on repolarization. , 1985, The Journal of pharmacology and experimental therapeutics.
[38] J. Mason. Drug therapy: amiodarone , 1987 .
[39] P. Kowey,et al. The effect of bretylium and clofilium on dispersion of refractoriness and vulnerability to ventricular fibrillation in the ischemic feline heart. , 1985, American heart journal.
[40] B. G. Benfey. Function of myocardial α-adrenoceptors , 1987 .
[41] H. Duff,et al. Amiodarone: biochemical evidence for binding to a receptor for class I drugs associated with the rat cardiac sodium channel. , 1989, Circulation research.
[42] M. Rosen,et al. Electrophysiologic effects of ketanserin on canine Purkinje fibers, ventricular myocardium and the intact heart. , 1989, The Journal of pharmacology and experimental therapeutics.
[43] W. Kannel,et al. Sudden unexpected death during ambulatory electrocardiographic monitoring. The Framingham Study. , 1983, The American journal of medicine.
[44] H. Hayashi,et al. Effects of pantethine on action potential of canine papillary muscle during hypoxic perfusion. , 1985, Japanese heart journal.
[45] D. Echt,et al. Evaluation of antiarrhythmic drugs on defibrillation energy requirements in dogs. Sodium channel block and action potential prolongation. , 1989, Circulation.
[46] J. Bigger,et al. NEW DRUGS. , 1979, Canadian Medical Association journal.
[47] S. Olsson,et al. Effects of acute and chronic beta-receptor blockade on ventricular repolarisation in man. , 1981, British heart journal.
[48] A. Gillis,et al. Clinical Pharmacokinetics of the Newer Antiarrhythmic Agents , 1984, Clinical pharmacokinetics.
[49] S. Nattel,et al. Concentration dependence of class III and beta-adrenergic blocking effects of sotalol in anesthetized dogs. , 1989, Journal of the American College of Cardiology.
[50] T. Ozawa,et al. Effects of antiarrhythmic agents classified as class III group on ischaemia‐induced myocardial damage in canine hearts , 1990, British journal of pharmacology.
[51] M. Fujiwara,et al. Relationship between the effects of Goniopora toxin on action potential and on contractile force in guinea-pig papillary muscle. , 1981, Japanese journal of pharmacology.
[52] P. Touboul,et al. Effects of intravenous sotalol in patients with atrioventricular accessory pathways. , 1987, American heart journal.
[53] H. Oinuma,et al. 4'-[(4-Piperidyl)carbonyl]methanesulfonanilides as potent, selective, bioavailable class III antiarrhythmic agents. , 1990, Journal of medicinal chemistry.
[54] B. Singh,et al. A third class of anti‐arrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474 , 1970, British journal of pharmacology.
[55] A. Varró,et al. Rate-dependent electrophysiological effects of OPC-8212: comparison to sotalol. , 1989, European journal of pharmacology.
[56] E. Williams. Is Phosphodiesterase Inhibition Arrhythmogenic? Electrophysiologic Effects in Pithed Rats and in Normoxic and Hypoxic Rabbit Atria of Enoximone, a New Cardiotonic Agent , 1987 .
[57] A. Mugelli,et al. Antiarrhythmic properties of naloxone: an electrophysiological study on sheep cardiac Purkinje fibers. , 1989, European journal of pharmacology.
[58] H. Selnick,et al. Suppression of Lethal Ischemic Ventricular Arrhythmias by the Class III Agent E4031 in a Canine Model of Previous Myocardial Infarction , 1990, Journal of cardiovascular pharmacology.
[59] C. Kawai,et al. Electrophysiological effects of melperone on isolated rabbit heart muscles , 1988, British journal of pharmacology.
[60] M Gwilt,et al. Selective class III antiarrhythmic agents. 1 Bis(arylalkyl)amines. , 1990, Journal of medicinal chemistry.
[61] H. Refsum,et al. Class III antiarrhythmic action linked with positive inotropy: effects of the d- and l-isomer of sotalol on isolated rat atria at threshold and suprathreshold stimulation. , 1988, Pharmacology & toxicology.
[62] L. Opie,et al. KC 8857, a new compound with combined bradycardic and positive inotropic effects , 1987 .
[63] A. Waldo,et al. Effects of N-acetylprocainamide on experimental atrial flutter and atrial electrophysiologic properties in conscious dogs with sterile pericarditis: comparison with the effects of quinidine. , 1987, Journal of the American College of Cardiology.
[64] S. Wong,et al. Synthesis and antiarrhythmic activity of novel 3-alkyl-1-[omega-[4-[(alkylsulfonyl)amino]phenyl]-omega- hydroxyalkyl]-1H-imidazolium salts and related compounds. , 1987, Journal of medicinal chemistry.
[65] P. Taggart,et al. Class III action of β-blocking agents , 1984 .
[66] Z. Szilvássy,et al. 7-oxo-PgI2 induced late appearing and long-lasting electrophysiological changes in the heart in situ of the rabbit, guinea-pig, dog and cat. , 1989, Journal of molecular and cellular cardiology.
[67] J. K. Gibson,et al. N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity. , 1991, Journal of medicinal chemistry.
[68] D. Roden,et al. Concentration-dependent pharmacologic properties of sotalol. , 1986, The American journal of cardiology.
[69] R. Fenici,et al. Effect of bunaphtine on right atrial repolarisation in man. , 1977, British heart journal.
[70] H. Refsum,et al. Class III Antiarrhythmic Action Linked with Positive Inotropy: Antiarrhythmic, Electrophysiological, and Hemodynamic Effects of the Sea‐Anemone Polypeptide ATX II in the Dog Heart in Situ , 1986, Journal of cardiovascular pharmacology.
[71] N. Taira,et al. Membrane current changes responsible for the positive inotropic effect of OPC-8212, a new positive inotropic agent, in single ventricular cells of the guinea pig heart. , 1987, The Journal of pharmacology and experimental therapeutics.
[72] N. El-Sherif,et al. Effects of clofilium on ischemic subendocardial Purkinje fibers 1 day postinfarction. , 1988, Journal of the American College of Cardiology.
[73] J. Mason,et al. Multicenter trial of sotalol for suppression of frequent, complex ventricular arrhythmias: a double-blind, randomized, placebo-controlled evaluation of two doses. , 1986, Journal of the American College of Cardiology.
[74] A. Jaffe,et al. Risk factors for sudden death after acute myocardial infarction: two-year follow-up. , 1984, The American journal of cardiology.
[75] M. I. Steinberg,et al. Clofilum--a new antifibrillatory agent that selectively increases cellular refractoriness. , 1979, Life sciences.
[76] F. Rockhold,et al. Cellular Electrophysiology of Clofilium, a New Antifibrillatory Agent, in Normal and Ischemic Canine Purkinje Fibers , 1981, Journal of cardiovascular pharmacology.
[77] T. Campbell,et al. Resting, and rate‐dependent depression of of guinea‐pig ventricular action potentials by amiodarone and desethylamiodarone , 1987, British journal of pharmacology.
[78] D. A. Lathrop,et al. Electromechanical characterization of the effects of racemic sotalol and its optical isomers on isolated canine ventricular trabecular muscles and Purkinje strands. , 1985, Canadian journal of physiology and pharmacology.
[79] W. Rogers,et al. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. , 1989, The New England journal of medicine.
[80] D. Wyse,et al. Electropharmacology of sotalol in patients with Wolff-Parkinson-White syndrome. , 1987, Circulation.
[81] H. Nakaya,et al. Electrophysiological effects of amosulalola new α- and β-adrenoceptor blocker, in isolated rabbit papillary muscles , 1986 .
[82] R. Shanks,et al. Indoramin-prolongation of repolarization time, a mechanism of bradycardia in man? , 1985, British journal of clinical pharmacology.
[83] B. Hoffman,et al. Effect of procainamide and N-acetylprocainamide on atrial flutter: studies in vivo and in vitro. , 1987, Circulation.
[84] K. Nademanee,et al. Pharmacokinetic Significance of Serum Reverse T3 Levels During Amiodarone Treatment: A Potential Method for Monitoring Chronic Drug Therapy , 1982, Circulation.
[85] J. Klaunig,et al. Amiodarone and Desethylamiodarone Toxicity in Isolated Hepatocytes in Culture 1 , 1989, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[86] C. January,et al. A Model for Early Afterdepolarizations: Induction With the Ca2+ Channel Agonist Bay K 8644 , 1988, Circulation research.
[87] M. Taams,et al. Prevention and Treatment of Supraventricular Tachycardia Shortly After Coronary Artery Bypass Grafting: A Randomized Open Trial , 1986, Angiology.
[88] A. Gomoll,et al. Comparative beta-blocking activities and electrophysiologic actions of racemic sotalol and its optical isomers in anesthetized dogs. , 1986, European journal of pharmacology.
[89] A. S. Harris. Delayed Development of Ventricular Ectopic Rhythms following Experimental Coronary Occlusion , 1950, Circulation.
[90] M. Aomine. Multiple electrophysiological actions of amiodarone on guinea pig heart , 1988, Naunyn-Schmiedeberg's Archives of Pharmacology.
[91] B. Lucchesi,et al. Effects of Pimobendan (UD‐CG 115 BS), a New Positive Inotropic Agent, on Ventricular Tachycardia and Ischemic Ventricular Fibrillation in a Conscious Canine Model of Recent Myocardial Infarction , 1988, Journal of cardiovascular pharmacology.
[92] B. Singh,et al. Acute and chronic effects of ketanserin on the electrophysiologic properties of isolated rabbit ventricular myocardium: particular reference to repolarization. , 1988, American heart journal.
[93] K. Kamiya,et al. Electrophysiological effects of OPC‐88117, a new antiarrhythmic agent on papillary muscles and single ventricular myocytes isolated from guinea‐pig hearts , 1989, British journal of pharmacology.
[94] B. Singh,et al. Historical development of the concept of controlling cardiac arrhythmias by lengthening repolarization: particular reference to sotalol. , 1990, The American journal of cardiology.
[95] P. Leveque. Anti-arrhythmic Action of Bretylium , 1965, Nature.
[96] J. Weirich,et al. Electrophysiological profile of KC 8857, a new bradycardic agent , 1987 .
[97] J. Sundsfjord,et al. Amiodarone inhibits the conversion of thyroxine to triiodothyronine in isolated rat hepatocytes. , 1984, Endocrinology.
[98] P. Somani. Basic and Clinical Pharmacology of Amiodarone: Relationship of Antiarrhythmic Effects, Dose and Drug Concentrations to Intracellular Inclusion Bodies , 1989, Journal of clinical pharmacology.
[99] G. Isenberg,et al. The role of sodium channels in the effects of the cardiotonic compound DPI 201-106 on contractility and membrane potentials in isolated mammalian heart preparations. , 1985, European journal of pharmacology.
[100] J. Parratt,et al. Antiarrhythmic actions of meptazinol, a partial agonist at opiate receptors, in acute myocardial ischaemia , 1983, British journal of pharmacology.
[101] H. Refsum,et al. Arrhythmogenic, antiarrhythmic and inotropic properties of opioids. Effects of piritramide, pethidine and morphine compared on heart muscle isolated from rats. , 1987, Pharmacology.
[102] A. Ferroni,et al. Electrophysiological aspects of the action of bunaphtide on single cardiac muscle fibres , 1973 .
[103] S. E. Freeman,et al. Blockade of a cardiac K+ channel by tacrine: interactions with muscarinic and adenosine receptors. , 1988, European journal of pharmacology.
[104] W. Osterrieder. 9‐Amino‐1,2,3,4‐tetrahydroacridine (THA) is a potent blocker of cardiac potassium channels , 1987, British journal of pharmacology.
[105] Effects of TYB-3823, a new antiarrhythmic drug, on the electrophysiological properties of guinea-pig ventricular muscles. , 1990, General pharmacology.
[106] R. Gomez,et al. Synthesis and cardiac electrophysiological activity of aryl-substituted derivatives of the class III antiarrhythmic agent sematilide. Potential class I/III agents. , 1990, Journal of medicinal chemistry.
[107] H Ichikawa,et al. Neural networks applied to structure-activity relationships. , 1990, Journal of medicinal chemistry.